Please ensure Javascript is enabled for purposes of website accessibility

InMode Ltd. (INMD) Q3 2019 Earnings Call Transcript

By Motley Fool Transcribing - Nov 6, 2019 at 6:01PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

INMD earnings call for the period ending September 30, 2019.

Logo of jester cap with thought bubble.

Image source: The Motley Fool.

InMode Ltd. (INMD 2.60%)
Q3 2019 Earnings Call
Nov 05, 2019, 9:00 a.m. ET


  • Prepared Remarks
  • Questions and Answers
  • Call Participants

Prepared Remarks:


Welcome to the InMode third-quarter 2019 earnings conference call. [Operator instructions] Please note, this event is being recorded. I would now like to turn the conference over to Miri Segal of MS-IR. Please go ahead.

Miri Segal -- Investor Relations

Thank you, operator, and good day to everybody. I would like to welcome all of you to InMode's third-quarter 2019 financial results conference call. With us on the line today are Mr. Moshe Mizrahy, chairman of the board and CEO; Mr.

Yair Malca, CFO; and Michael Kreindel, CTO. Before we begin, may I remind our listeners that certain information provided on this call may contain forward-looking statements, and the safe harbor statement outlined in today's earnings release also pertains to this call. If you have not received a copy of the release, please view it in the Investor Relations section of the company's website. Changes in business, competitive, technological, regulatory and other factors could cause actual results to differ materially from those expressed by the forward-looking statements made today.

Our historical results are not necessarily indicative of future performance. As such, we can give no assurance as to the accuracy of our forward-looking statements and assume no obligation to update them, except as required by law. Moshe will begin the call with the business update, followed by Yair with an overview of the financials. We will then open the call for the question-and-answer session.

I'll now hand over the call to Mr. Moshe Mizrahy, InMode's CEO. Moshe, please go ahead.

Moshe Mizrahy -- Chairman of the Board and Chief Executive Officer

Thank you, Miri, and thanks to all of you for joining our third-quarter financial results conference call. I would like to welcome everyone to our first quarterly earning call as a public company since our IPO on -- which took place on August 8 this year. I'm sure that many of you are already familiar with the InMode story from our road show presentation and from meetings with some of you. And for those of you who will hear the story for the first time today, I hope that we will communicate the message clearly.

Before I start, I want to present the [Inaudible] around the table in our office in Israel. With me, of course, Dr. Michael Kreindel, co-founder, our CTO and also a member of the board. Yair Malca, our CFO; Rafi Likerman, our VP, Finance.

I will start by updating you with the major developments that have positively affect our company since the IPO. As to the first one, as presented in the road show, we launched the Evolve platform to the U.S. market. Evolve is the first hand-free platform with 3 treatment modality: skin tightening, fat destruction and muscle simulation, what we call EMS.

Although the launch was only in the United States, but it was very successful in the fourth quarter. Second, as part of our global expansion strategy, we have established two fully owned sales and marketing subsidiary, one in India and one in Australia. We have already hired salespeople and management team in each of those two subsidiaries. This initiative will help us to sell our product portfolio directly to the doctor and not through distributors.

Third, we established business plan and contacts in two other countries in Europe and Asia for establishing two additionally fully owned subsidiary for marketing and sales in 2020. By the end of 2020, we would like to have full direct operation in eight territories: the United States, Canada, Spain, the U.K., India, Australia and two more country, as I said, one in Europe and one in Asia. Third, we are continuing to receive regulatory approval for our unique product lines. We recently received approval in Canada, and we reported that.

For the Morpheus8, our second-generation fraction allowance device, and for our RFAL, radio-frequency assisted lipolysis technology, which cover all the BodyTite, FaceTite, AccuTite application. We also received CE Mark approval in Europe for Morpheus8 and also for the FormaV for women health application. In addition to that, we are currently managing five regulatory processes around the world, in Taiwan, TFDA; in Korea, KFDA; in Brazil, Anvisa; in China, CFDA; and in Singapore. And all this is in addition to two filings that we made recently with the FDA and additional two filings with the CE in Europe.

So altogether, we have right now pending something that's close to at least 10 to 12 new approval, which we expect to get for all regulatory body around the world. Hopefully, all of them will be in effect in 2020, OK? We are continuing to grow worldwide. As of September 30, our total employee was 232 people, excluding manufacturing, out of which, 107 direct salespeople. Before we continue to update you with the financial results for Q3, I would like to reemphasize InMode's core business and competitive advantage.

These competitive advantages help us to maintain our leadership position and momentum for years to go. InMode is the leading global provider of innovating minimally invasive surgical aesthetic and medical treatment solution. Our proprietary products are designed to address, first, face and body contouring, medical aesthetic and women health using minimally invasive bipolar radio frequency energy. Minimally invasive bipolar RF energy represents a paradigm shift in the aesthetic surgery market, offering an alternative to conventional surgery while significantly minimizing risk of scarring, downtime, anesthesia, pain and other complication that are typical in surgical procedure.

In addition, we design, differentiate noninvasive medical aesthetic products as well that include fat killing and skin tightening simultaneously, permanent fat reduction using our innovative dual wavelength technology and other treatment targeting skin appearance and texture to our high-power intense pulsed light technology. Our competitive advantage is based on six competitive element, which we will maintain as long as we are keeping the momentum. The first one is our IP. We believe that we have a very strong IP on all of our base technologies, which have been registered in several countries.

So far, no one has tried to copy these technologies since we believe that everyone knows that our IP cover the technology very well. To summarize, we believe that our minimally invasive RF bipolar IP will provide us with the protection and advantage over years to come. The second competitive advantage is our know-how. During the last 10 years, we have developed knowledge and know-how with regard to how to design minimally invasive bipolar RF devices for aesthetic surgery and other surgical procedure.

This know-how -- this knowledge cover hardware, software and mechanical engineering. The third element is our clinical base. Since our initial introduction to the market, we have published over 40 peer-reviewed articles in the best magazines on this technology and on our technologies and indications. We are the leaders of the research of minimally invasive bipolar RF clinical science.

The fourth element -- the fourth competitive element is our luminary base. We have developed a group of luminary and opinion-leading doctors who are also surgeon that conduct our study. And they are a great supporter of our technology. It will be very difficult for anyone in our -- of our competitors to develop such unique group of luminary and opinion-leading doctors.

The fifth competitive advantage element is the regulatory approval. We passed all the regulatory approval processes in many countries. This process take years since the regulatory bodies around the world ask for a long follow-up. We believe that this is a significant barrier of entry to other competitors.

The sixth element is our branding. We own the brand BodyTite, FaceTite, NeckTite, AccuTite, Morpheus8 and others, which are becoming increasingly well-known brand names. We have already sold 4,400 system worldwide. We're definitely considered pioneer in the industry with a strong marketing and brand position.

In the third quarter of 2019, InMode generates record revenue of $40 million, a 57% increase from the same period in 2018, reflecting our continued growth and the increased adoption of our minimally invasive bipolar RF technology around the world. Net income increased by 87% to over -- year-over-year to $16.2 million in the third quarter, up from $8.6 million in the same period in 2018. We are focusing on profitable growth and are successfully pursuing our goal of international expansion, driven largely by Europe and Asia Pacific. We're increasing this expansion effort with our subsidiary established in India and Australia and more to come, which both also a large target market seeking minimally invasive technology that address the need of plastic surgery, cosmetic surgery and women health.

Having boots on the ground provide us with direct contact with our customers, ensuring understanding of the need and how to effectively address them, and I mean the doctors. We have diversified product portfolio. Most of our revenue in the quarter was generated from our BodyTite Embrace, Optimas and Votiva. So we are not dependent on any individual product.

Now let me hand over the call to Yair. He will review and give you more detail on our financial results. And after that, we will open it to Q&A. Please, Yair.

Yair Malca -- Chief Financial Officer

Thanks, Moshe. Good day, everyone. Total revenue in the third quarter of 2019 grew 57% to $40 million, with gross margin of 87%. Operating expenses in the quarter totaled approximately $19 million, a 42% increase from the previous year.

The increase is due largely to our expanded sales and marketing efforts. Operating margin in the quarter was 40%, compared to 33% for the same period in 2018. Earnings per share in the quarter were $0.42 per diluted share, compared to $0.26 in the previous year, an increase of 62%. We completed the third quarter with a strong balance sheet.

As of September 30, 2019, the company had cash and cash equivalents, marketable securities and deposits of $166.3 million. Out of which, $70 million are net proceeds raised at a recent IPO. On the cash flow front, across the first nine months of 2019, the company generated $34.8 million from operating activities. With that, I will turn the call back to Moshe.

Moshe Mizrahy -- Chairman of the Board and Chief Executive Officer

Okay. Thank you, Yair. Now we're pleased to open to question. Miri, do you want to handle this session?

Questions & Answers:


[Operator instructions] The first question comes from Jack Meehan of Barclays. Please go ahead.

Jack Meehan -- Barclays -- Analyst

Thank you. Good morning, good afternoon, and congrats on the first quarter out of the gate. Just my first question, the revenue came in better than we were expecting. I heard the update is where you stood at August in terms of the commercial hiring, but I was wondering, as you look forward in the U.S., what are your expectations for additional sales hires in terms of the numbers? Where do you expect to end 2019? And what's a good run rate into 2020? And then internationally, could you just give us some color on what some of the efforts you put in in Europe and Asia to drive growth?

Moshe Mizrahy -- Chairman of the Board and Chief Executive Officer

Yeah. Thank you, Jack. Thank you. Yes, I will answer your question.

Currently, North America, we have 96 direct sales, sales rep. Our plan for 2020 is to grow to 115, between 110 and 115. Direct salespeople in the rest of the world right now is about 11 people, and we would like to grow in 2020 by at least another 12 by opening more subsidiaries. As regard to 2019, our target revenue was between $146 million to $148 million.

We are now raising the target to $150 million, $152 million. As we go to 2020, we will give the target in the next conference call.

Jack Meehan -- Barclays -- Analyst

Great. That's helpful. And then maybe could you just give us some color on where you're seeing traction with the BodyTite family? Just in the quarter, could you give us a sense for how many systems you placed and where you are seeing demand from a customer perspective? And then finally, just how is the AccuTite launch contributing to that? Has that been a driver of the BodyTite placements?

Moshe Mizrahy -- Chairman of the Board and Chief Executive Officer

The answer, yes, absolutely. As we add more hand pieces to the BodyTite, Embrace platforms, we sell upgrade to existing customers, and we sell the new platforms with the new hand pieces. As you know, we do not want to release, and we will, the numbers of platforms that we're selling every quarter by names or by category. The only thing I can tell is that we continue to sell across three segments of our business, which is minimally invasive, which includes a BodyTite, FaceTite, NeckTite, AccuTite, Embrace and Morpheus8, all the ablative product; and the second segment is aesthetic, which is the noninvasive RF IPL laser for more, I would say, conventional aesthetic treatment; and the third part of our -- or the third segment is women health, which we introduced to the market a few new indication using the AccuTite for labiaplasty and others.

Other than that, I don't think we want to reveal the numbers of individual platforms, but again, as I said in my presentation, we do not depend on one product. We're selling across the line.

Jack Meehan -- Barclays -- Analyst

Great. Last question. The gross margins at 87.4% came in above what we were looking for in the quarter. What do you attribute the leverage on that line, too? And what's a good run rate moving forward? Was there anything outsized which contributed to the upside in the quarter?

Moshe Mizrahy -- Chairman of the Board and Chief Executive Officer

OK. First, before I answer your question, I want to say something so everybody will understand. Gross margin of above 85% for InMode is a must. It's not nice to have.

What does it mean? It means that every time that we go back to the drawing board to design the next platform, and we're designing at least two new platforms every year, on the drawing board, we have all kind of formulation to calculate that the systems that we're designing will have 85% gross margin. Otherwise, we do not start. Unless we have 85% to 87% gross margin, we will never be able to invest 45% in marketing, in R&D and other and have a nice profit, which is the most important objective of the firm, I would say. Therefore, we will continue to maintain this level, either it will be 85%, 86% to 87%, it depend on the mix of the product that we manufacture.

If the mix is more RF-based, then it's [Inaudible] 87%. If the mix is more laser and IPL, it's [Inaudible] 85%. If we sell more on the international market, where we recognize only the transfer price and not the full value of the system, then gross margin go a little bit below 85%. But on average, we will keep at least 85% gross margin on any combination product or any portfolio that we will have in the future.

Does that answer your question?

Jack Meehan -- Barclays -- Analyst

It did. So -- but also -- and I really appreciate that feedback. Just in the quarter itself, was there any -- because it obviously did a lot better in the quarter, was there anything that contributed? Should we expect it kind of drops closer to 85% in the fourth quarter? What are you thinking?

Moshe Mizrahy -- Chairman of the Board and Chief Executive Officer

You mean on the fourth quarter?

Jack Meehan -- Barclays -- Analyst

Yes. So just looking forward, is this a good run rate? Or should we just assume 85% of [Inaudible]?

Moshe Mizrahy -- Chairman of the Board and Chief Executive Officer

Yeah, yeah. [Inaudible]. Yes. The answer is yes.

It will be probably the same as the third, plus/minus 1%. You never calculate it by a fraction of a percentage.

Jack Meehan -- Barclays -- Analyst

Sure. I appreciate it, Moshe.


The next question comes from Matt Taylor of UBS. Please go ahead.

Matt Taylor -- UBS -- Analyst

Hi. Thank you for taking my question, and congrats on a good quarter. So I just wanted to ask a little bit more about the pipeline. Can you talk about the platforms that you were planning to launch here in the second half of the year, first, the noninvasive, hands-free devices for body and face and also the [ CelluTite ] application? How are those rolling out? What's the reception been like? Any other color that you can provide would be great.

Moshe Mizrahy -- Chairman of the Board and Chief Executive Officer

OK, OK. I will, I will. Thank you, Matt. How are you?

Matt Taylor -- UBS -- Analyst

I'm doing great. How are you?

Moshe Mizrahy -- Chairman of the Board and Chief Executive Officer

We're fine. Working hard but we're fine. Yes, the Evoke. First of all, the Evolve, we launched the Evolve in the U.S.

in the last month, in the last quarter, and we continue in the fourth quarter. We will launch it in the rest of the world in the first quarter of 2020. We're still waiting for the final approval by the CE for Europe of the Evolve, which is the body hand-free device. But it will come.

It's coming. We're almost at the end. Right now, regulatory become a bottleneck. You need to spend more money and attention to get it.

But we're -- we know how to do it. We have a good regulatory department here that actually file worldwide with some assistance from consultants. So this is the Evolve. The Evoke, the hand-free face treatment platform, is pending FDA approval.

Hopefully, it will come soon. The system is almost ready. We're waiting for the approval. And we're even starting to manufacture some pieces in order to launch it once we have the approval.

I believe it will come either at the end of this quarter or the first of next quarter. I'm sure you understand that the FDA is more sensitive with the face, and they ask many question to make sure that it's safe. And the efficacy is according to what we said. We have done all kind of in vivo and animal testing to show them the study and to show them the safety.

And hopefully, it will come soon. The same with [ CelluTite ]. The [ CelluTite ] right now is already FDA-approved, but we are waiting to see the results from the study that we are making from the United States to finalize the protocol. So these two platforms, as we promised in the road show, we either enter the market toward the end of this quarter, but I believe it will be better to do it right and to launch those two products sometime in the first quarter of 2019 -- 2020, excuse me.

Other -- we have other products in the pipeline like the EMS device and some new Morpheus tips, but these are in the engineering phase, and it will come sometime in 2020. Did I answer your question?

Matt Taylor -- UBS -- Analyst

Yes, you did. And I just had one follow-up based on that. So firstly, I just was wondering, given you had -- sorry, Evolve launched early last quarter, can you talk about the early uptake of that? How are customers responding to it? Was there actually material sales in Q3?

Moshe Mizrahy -- Chairman of the Board and Chief Executive Officer

Material sales. Yeah, it will -- what I can say, it was a successful launch. We saw quite a few in Q3. And we have some backlog, which we are basically supplying in Q4.

We increased manufacturing capacity of the Evolve recently. And now we're producing about 25 every week. So it's coming, and it's going to be successful worldwide.

Matt Taylor -- UBS -- Analyst

Thank you. And then just one follow-up on that. So I guess with Evoke coming a quarter or two later, I mean, obviously, the results in Q3 were very strong, despite not having any sales of that. I know you don't want to talk about the specific numbers of boxes, but is there one or two areas this quarter that were very strong that you saw an acceleration in demand? Is there any high-level color that you can provide to help us understand how different areas of the business are performing?

Moshe Mizrahy -- Chairman of the Board and Chief Executive Officer

Well, the Evolve, the hand-free device, was actually sold only in the U.S., and it was 9% from our business in the fourth quarter, close to $3.7 million if I have to be precise. So that was the nice contribution to Q3, and it will continue to contribute in Q4 and in 2020 as well.

Matt Taylor -- UBS -- Analyst

OK. Great. Thank you. I'll step back in the queue.


The next question comes from Kyle Rose of Canaccord Genuity. Please go ahead.

Kyle Rose -- Canaccord Genuity -- Analyst

Great. Good morning, and good afternoon, everybody. Thank you for taking the questions, and congrats on a strong quarter. So a lot has been asked, but I guess I just wanted to talk -- you put out a press release, I think, back in late August, early September just about a user meeting.

Maybe you can help us understand kind of the feedback from the user meeting and kind of how that helps inform your view of the product development and kind of the market opportunity for some of these new products. And then when you think about 2020, opening up two markets, it sounds like one in Europe, one in Asia Pacific. Maybe just help us understand the potential for the size and the investments that need to happen to open up those opportunities. Is that something to happen in the first half? Can we see the revenue growth from the second half? Just kind of flesh that out for us.

Moshe Mizrahy -- Chairman of the Board and Chief Executive Officer

OK. First, I will start with your second question, OK? The country in Europe that we're talking about, and you can guess, is one of the big -- biggest countries. I'm not talking about Belgium. We're not opening fully owned or joint venture controlled by us in a country that will contribute a few million dollars a year.

We would like a few hundred thousand dollars a year. We would like to open in a country where the investments will pay off. And of course, it will be one of the biggest countries. In Asia, I can tell you, we're talking about China.

We are trying to open something in China. We have a small company in Guangzhou. And once we get the CFDA approval, we will start operating commercially in China, direct and through some distributor. In China, you cannot go just direct, you have to combine, because China is big territory.

Sometime, there's a different mentality. We are learning this right now, doing some homework in order to be prepared for the time that the CFDA will allow us to start. We're in the process of getting CFDA for the InMode RF, for the minimal invasive and also for the InMode. As for your first question regarding the user meeting, the user meeting was the first time we did -- was the first time that the InMode actually did such meeting.

And it was just good for the doctors to share information. We had something like, I don't know, six to eight lectures every day. It was for two days. Attendance was about 600 people, which is very unique for the first user meeting.

We intend to continue to do it. Some doctor share some of the experience, some doctor ask question about adverse effect. They try to share protocols and to understand which protocol was better. I think it's good, especially for doctors.

It's a community. It's a community like the family of InMode, and we will continue to do it. We're learning from the first time. And the next time will be organized, I believe, even better with some experience that we have from the first time.

But it was quite success.

Kyle Rose -- Canaccord Genuity -- Analyst

Great. And then just one follow-up for me. Just you've got a nice war chest of cash piling up, both from the recent financing in the IPO, but then also from just cash flow from operations. I guess how should we think about deployment of capital on a go-forward basis? I mean your expectations for product development and gross margins are very clear, but should we expect you to be acquisitive on a go-forward basis? Just how do you view your cash utilization moving forward? Thank you.

Moshe Mizrahy -- Chairman of the Board and Chief Executive Officer

Well, we have close to $170 million. And I will not tell you today that we have -- we know how to deploy $170 million. No. But we have three area where we will invest heavily.

First, when you establish a subsidiary, you need millions of dollars. You hire people. You have real estate. You need training.

You need to give them demos. You need to keep inventory, working capital. It's an investment, and this is coming from the same source. Second, if the opportunity will present itself, and we will be able to acquire complementing technology that will enable us to design something which will complement our product line, we will do it.

Licensing or buying technology. And there are some technologies that we're considering right now. We're checking. We have some people coming to us with technologies that relate to wellness, aesthetic, etc.

So this is also something that we might consider. All the rest is increasing our capacity of manufacturing, and that costs money. I will not say it costs $170 million, but it costs money, and we are now establishing a few more lines. Probably, we will increase our production capacity by one-third next year.

And we're doing it right now, and this is also our deploying money on all kind of manufacturing facilities, all kind of testing equipment, all kind of fixtures and having and buying inventory of component. This is also another. But at the end of the day, we're generating -- you can see that we're generating about $16 million to $18 million every quarter, which is a lot of money, basically, is our net profit. And so I assume that the money will continue to accumulate until we have some good reason to invest tens of millions of dollars.

Right now, we do not have.


Is there a follow-up, Mr. Rose.

Kyle Rose -- Canaccord Genuity -- Analyst

No. Thank you for taking the question.


Thank you. [Operator instructions] The next question comes from Jeff Johnson of Baird. Please go ahead.

Jeff Johnson -- Robert W. Baird and Company -- Analyst

Thank you. Good morning, good afternoon, guys. Just a couple of follow-up questions for me. First, Moshe, did I hear you correctly, I joined the call a little late, that you do have EMS indications approved on Evolve? And then on Evoke, I know you're talking about an approval late this year, early next.

We did just see an FDA approval on a product called [ EMface E-M face ]. Just wondering what that product is. We thought that might be Evoke, but it sounds like it must not have been.

Moshe Mizrahy -- Chairman of the Board and Chief Executive Officer

Yeah. The [ EMface ], it's a preliminary on the Evoke. We got the approval on one indication. We're waiting for the second one.

So we will launch them together. You're right. This is a product. As we go to the EMS on the Evolve, it is not yet FDA-approved.

Once it will be approved, we will be able to launch it to the market on the Evolve. But the EMS will be also -- be launched on the Votiva and other platform as well.

Jeff Johnson -- Robert W. Baird and Company -- Analyst

All right. That's helpful. And then on the women's healthcare platform, obviously, there's just been a lot of noise in the past year on there, and you seem to be sitting well compared to some of your competitors in that area. So any color you can provide on that part of the business this quarter, what it grew, how to think about the women's healthcare business over the next several quarters?

Moshe Mizrahy -- Chairman of the Board and Chief Executive Officer

Yeah. The women health business, you know that all the industry had a program in the middle of last year, in 2018, when everybody received the letter from the FDA. Several companies left the market like Lumenis and Cynosure and others. Those company have used a laser to do ablation in the vaginal wall.

Since we're using RF, which is nonablative and noninvasive technology, the FDA received our answer to the letter, and we are, well, cleared by the FDA to continue to sell it. So actually, this market, after the FDA letter, went down significantly, and we're picking up again. Right now, it's about 16% of our business. But by adding more indication to the same platform, we hope that that will grow again to the level of 20 and above, 20% and above.

Jeff Johnson -- Robert W. Baird and Company -- Analyst

Great. That's helpful. And last question for me. Just on the new relationships in India and Australia, was there any contribution from inventory loading to those dealers in the third quarter? Or can we use this kind of $9 million international revenue number for the third quarter is a good jumping-off point to think about how we grow that number over the next several quarters? Thank you.

Moshe Mizrahy -- Chairman of the Board and Chief Executive Officer

Yes. In Australia, there's none. We just hired the general manager and two more people. So their contribution to the third quarter was not exist.

The Indian was the first quarter that we're actually selling, and the revenue in India was around $280,000 to $300,000.

Jeff Johnson -- Robert W. Baird and Company -- Analyst

Thank you.


And we have a follow-up from Matt Taylor of UBS. Please go ahead.

Matt Taylor -- UBS -- Analyst

Hi. Thanks for taking the follow-up. I just wanted to ask about margins longer term. Since you had really strong margins this quarter and you talked about your commitment to 85% plus gross margin products, I guess, given the high-margin number that we saw in Q3, does that give you more confidence in your gross margin trajectory over the next couple of years, if we actually see gross margins expand? Can you talk a little bit about those dynamics? Thank you.

Moshe Mizrahy -- Chairman of the Board and Chief Executive Officer

No, I think we are in some kind of a balance. I think to grow above 85% to 87% will be very difficult, and we don't want to jeopardize the quality of the system. Of course, we can buy cheaper components and try to do cheaper, but I don't think it's necessarily having 85% to 87%. I do believe that we will continue to maintain this gross margin level between 85% to 87%, depends on the platform, depends on the territory, depends on the [Inaudible] price.

I don't think it will go up to above that.

Matt Taylor -- UBS -- Analyst

OK. All right. Thank you very much.


This concludes our question-and-answer session. I would like to turn the conference back over to Moshe Mizrahy, chairman and CEO, for any closing remarks.

Moshe Mizrahy -- Chairman of the Board and Chief Executive Officer

OK. Again, thank you, everybody, for joining us. We will welcome you again within three months in our end-of-year earning call, and have a good day. Thank you very much.



[Operator signoff]

Duration: 39 minutes

Call participants:

Miri Segal -- Investor Relations

Moshe Mizrahy -- Chairman of the Board and Chief Executive Officer

Yair Malca -- Chief Financial Officer

Jack Meehan -- Barclays -- Analyst

Matt Taylor -- UBS -- Analyst

Kyle Rose -- Canaccord Genuity -- Analyst

Jeff Johnson -- Robert W. Baird and Company -- Analyst

More INMD analysis

All earnings call transcripts

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

InMode Ltd. Stock Quote
InMode Ltd.
$23.25 (2.60%) $0.59

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.